drugset / Trial / NCT05553314

Carvedilol in HF With Preserved EF

NCT05553314

RandomizedParallel-groupDouble-blindTreatment

Summary

Beta-blockers improve clinical outcomes in heart failure and reduced ejection fraction (HFrEF); but not in those with preserved EF. Global longitudinal strain (GLS) is a prognostic factor independent of left ventricular ejection fraction (LVEF). In a retrospective with 1969 patients with HF and LVEF of ≥40%, beta-blocker was associated with improved survival in those with low GLS (GLS \<14%), but not in those with GLS ≥14%. In this prospective, randomized clinical study, the investigators will assess the effect of slow-release carvedilol in patients with HFpEF and hypertension. The primary endpoint is the time-averaged proportional changes in NT-proBNP level and GLS change from baseline to month 6.

Timeline

Start
2021-11-17
Primary completion
2026-01-08
Completion
2026-01-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Carvedilol Other / unclassified 8 mg
Subject Carvedilol Other / unclassified 16 mg
Subject Carvedilol Other / unclassified 32 mg
Subject Carvedilol Other / unclassified 64 mg